Clearance Summary
MODIFICATION TO VYSIS UROVYSION BLADDER CANCER RECURRENCE TEST received FDA 510(k) clearance under submission number K033982, sponsored by Vysis. The device was reviewed via the Special premarket notification pathway and assigned to the Immunology review panel. The statutory decision date of record is 2004-01-22.
- Submission: K033982
- Applicant / Sponsor: Vysis
- Clearance pathway: Special
- Review panel: Immunology
- Device class: Class II
- Regulation citation: 21 CFR 866.6010
- Decision date: 2004-01-22
Classification & Regulation
This clearance is catalogued under FDA product code MMW and 21 CFR 866.6010, within the Immunology review panel as a Class II device.